“PASCAL未来有望成为年销售额突破10亿美元的重磅炸弹级产品。”*本文仅代表作者观点，不代表知联社立场美国时间2026年1月14日，杭州启明医疗器械股份有限公司（以下简称“启明医疗”）子公司Cardiovalve Ltd.（以下简称“Cardiovalve”）一纸诉状，将全球心脏瓣膜巨头Edwards Lifesciences Corp.及其关联公司（以下合称“Edwards”）诉至美国...
Source Link“PASCAL未来有望成为年销售额突破10亿美元的重磅炸弹级产品。”*本文仅代表作者观点，不代表知联社立场美国时间2026年1月14日，杭州启明医疗器械股份有限公司（以下简称“启明医疗”）子公司Cardiovalve Ltd.（以下简称“Cardiovalve”）一纸诉状，将全球心脏瓣膜巨头Edwards Lifesciences Corp.及其关联公司（以下合称“Edwards”）诉至美国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.